Pharmakokinetik von Imatinib (STI571) und seinem Hauptmetaboliten N-Desmethyl-Imatinib

E. Schleyer; O.-G. Ottmann; T. Illmer; S. Pursche; T. Leopold; M. Bonin; J. Freiberg-Richter; A. Jenke; U. Platzbecker; M. Bornhäuser; G. Ehninger; P. le Coutre

doi:10.1055/s-2004-813484

TumorDiagnostik & Therapie, Table of Contents

TumorDiagnostik & Therapie 2004; 25(4): 192-196
DOI: 10.1055/s-2004-813484

Symposium Report

Pharmakokinetik von Imatinib (STI571) und seinem Hauptmetaboliten N-Desmethyl-Imatinib

Pharmacokinetics of Imatinib and its Main Metabolite N-desmethyl-imatinibE. Schleyer¹ , O.-G Ottmann² , T. Illmer¹ , S. Pursche¹ , T. Leopold¹ , M. Bonin¹ , J. Freiberg-Richter¹ , A. Jenke¹ , U. Platzbecker¹ , M. Bornhäuser¹ , G. Ehninger¹ , P. le Coutre³

¹Universitätsklinik Carl Gustav Carus Dresden
²Klinikum der Wolfgang Goethe Universität Frankfurt
³Medizinische Klinik m. S. Hämatologie und Onkologie, Virchow Campus, Charité Humboldt Universität Berlin

Abstract

Schlüsselwörter

GIST - Imatinib - STI 571 - N-Desmethyl-Imatinib - Pharmakokinetik

Full Text

References

Literatur

1 Druker B J, Talpaz M, Resta D J. et al . Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. N Engl J Med. 2001; 344 1031-1037
2 Kantarjian H M, O’Brien S, Cortes J E. et al . Treatment of philadelphia chromosome-positive, accelerated-phase chronic myelogenous leukemia with imatinib mesylate. Clinical Cancer Research. 2002; 8 2167-2176
3 Sawyers C L, Hochhaus A, Feldman E. et al . A phase II study to determine the safety and antileukemic effects of STI571 in patients with Philadelphia positive chronic myeloid leukemia in myeloid blast crisis. Blood. 2000; 96 503 a
4 Hochhaus A, Kantarijan H M, Sawyers C L. et al . Glivec® (Imatinib Mesylate, STI571) induces hematologic and cytogenetic responses in the majority of patients with chronic myeloic leukemia in late chronic phase: results of a phase II study. Hematol. 2001; J 1 (Suppl) 199
5 Druker B J, Sawyers C L, Kantarjian H. et al . Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome. N Engl J Med. 2001; 344 (14) 1038-1042
6 Ottmann O G, Sawyers C L, Druker B. et al . Phase II study of STI571 in adult patients with Philadelphia chromosome (Ph) positive acute leukemias. Hematol. 2001; J 1 (Suppl) 93
7 le C outre P, Tassi E, Varella-Garcia M. et al . Induction of resistance to the Abelson inhibitor STI571 in human leukemic cells through gene amplification. Blood. 2000; 95 1758-1766
8 Bakhtiar R, Lohne J, Ramos L. et al . High-throughput quantification of the anti-leukemia drug STI571 (GleevecE) and its main metabolite (CGP 74 588) in human plasma using liquid chromatography-tandem mass spectrometry. Journal of Chromatography B. 2002; 768 325-340
9 Heinzel G, Hammer R, Wolf M. et al . Model building in pharmacokinetics/Part III: Simplified rules for the deduction of analytical solutions for linear compartment models. Arzneimittelforschung. 1977; 27 904
10 Peng B, Dutreix C, Mehring G. et al . Absolute bioavailability of imatinib (Glivec) orally versus intravenous infusion. J Clin Pharmacol. 2004; 44 158

PD Dr. med. Eberhard Schleyer

Medizinische Klinik und Poliklinik I an der Technischen Universität Dresden

Fetscherstr. 48

01307 Dresden

Phone: ++ 49/3 51/4 58-45 15

Fax: ++49/3 51/4 58-53 62

Email: schleyer@mk1.med.tu-dresden.de